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Abstract 
 
Variability in the tumorigenic potential among cancer cells within a tumor population is 
an unresolved fundamental issue in cancer biology. It is important to know whether 
cancer cells with higher tumorigenic potential, such as cancer stem cells, are only a small 
subpopulation.  We attempt to address the question of variability in tumorigenic potential 
based on the heterogeneity in apoptosis resistance of cancer cells. We use stochastic 
differential equations and kinetic Monte Carlo simulations to explore the mechanisms 
that generate cell-to-cell variability in apoptosis resistance of cancer cells. In our model, a 
simplified scheme of apoptosis signaling reactions is developed focusing on the 
proapoptotic Bid-Bax reaction and its inhibition by Bcl-2 like antiapoptotic proteins. We 
show how a combination of low probability Bid-Bax reaction along with overexpressed 
reactant molecules allows specific killing of cancer cells, especially under targeted 
therapy such as Bcl-2 inhibition.  This low probability Bid-Bax reaction protects normal 
cells from accidental apoptosis but generates cell-to-cell stochastic variability in 
apoptotic activation of cells equipped with overexpressed Bid and Bax molecules. We 
further demonstrate that cellular variations in Bcl-2 / Bax ratio, within a cancer cell 
population, can affect the intrinsic fluctuations arising from the stochastic Bid-Bax 
reaction and thereby provides a mechanism for origin of cells with higher tumorigenic 
potential. We discuss the implications of our results for cancer therapy, such as, optimal 
strategies to minimize stochastic fluctuations in cancer cell death.  
 1 
Introduction 
 
Variability in the tumorigenic\leukaemogenic potential among cancer cells has led to the 
hypothesis of cancer stem cells (1,2). Existence of such specialized class of cancer cells is 
an unresolved fundamental issue in cancer biology that has significant implications for 
cancer treatment (1-4). Previous experimental studies have indicated that only rare 
population (< 0.1%) of cancer cells possess the ability to form tumors when transplanted 
into immunodeficient NOD / SCID mice (3,5-7).  Recent in vivo studies, using highly 
immunocompromised NOD / SCID IL-2rg-/- mice, however, shows that a large fraction 
(~ 25%) of melanoma cancer cells could form tumors (4). Thus one is faced with two 
related questions in cancer biology: (i) how to characterize the subset of cancer cells that 
can be labeled as cancer stem cells, and (ii) what fraction of cancer cells has the 
tumorigenic potential. We attempt to answer these fundamental questions on the basis of 
heterogeneity in the apoptosis resistance of cancer cells.   
 
Mathematical and computational approaches are well suited to clarify the basis of cell-to-
cell stochastic variability in apoptotic activation through the intrinsic (mitochondrial) 
pathway of cancer cells. In our proposed computational model, the basis of disparity in 
tumorigenic potential of cancer cells lies in the cell-to-cell variability in apoptotic 
resistance of cancer cells. Part of this cell-to-cell variability originates from inherent 
stochastic fluctuations (8-12) in apoptotic activation of cancer cells. Such stochastic 
activation would support the possibility that all cancer cells have similar but low 
proliferating potential in in vitro colony forming assay or in vivo transplantation assay 
(1). Cell-to-cell variability in apoptosis resistance can also arise from cellular variability 
in concentrations of key apoptotic regulators such as Bcl-2 (11-13). This type of 
variability might help isolate a phenotypically distinct population such as CD34+CD38- 
leukemic stem cells and supports a model where only a small subset of cancer cells 
posses extensive proliferating potential (5-7). Computational study of the intrinsic 
pathway of apoptosis allows us to estimate the contributions of both inherent stochastic 
fluctuations and cellular variations in protein levels in generating cell-to-cell variability 
in apoptosis resistance of cancer cells.  
 
It has been shown that BH3 mimetic molecules such as HA14-1 or ABT-737 can 
selectively kill cancer cells leaving normal cells unharmed (11,12,14-20). Such increased 
potential for apoptotic activation in cancer cells can be explained by high expression 
levels of Bid-like (BH3 only activators) and Bax-like (multidomain proapoptotic) 
molecules in cancer cells and assuming that Bid-Bax reaction is a low probability event. 
In this study, we focus on the pre-mitochondrial signaling module to elucidate how 
cancer cells, but not normal cells, have a greater chance of getting activated through the 
Bid-Bax reaction. Increased expression of apoptotic inhibitors, such as Bcl-2 proteins 
(21-23), would prevent Bid-Bax reaction and thus protect cancer cells from apoptotic 
death. In addition, a fraction of cancer cells, such as the CD34+CD38- phenotype of 
leukemic stem cells (5-7), can become particularly resistant to apoptotic stress due to 
pronounced overexpression of Bcl-2 like antiapoptotic proteins. Once the apoptotic 
inhibition of Bcl-2 proteins is overwhelmed by BH3 mimetic molecules, cancer cells 
become vulnerable to apoptotic death and more so than normal cells. Even though a low 
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probability Bid-Bax reaction and its Bcl-2 inhibition can be postulated, lack of 
measurements of Bid-Bax reaction constants and Bid/Bax/Bcl-2 protein levels makes any 
quantitative study of apoptotic activation in cancer cells difficult. We first use a 
computational approach to estimate a possible range in Bid-Bax reaction constant that is 
further used in subsequent simulations.  
 
We study the intrinsic pathway of apoptosis in which the activation is initiated through 
the regulatory loop created by Bid-Bax-Bcl-2. A stochastic differential equation based 
model elucidates the inherently stochastic nature of Bid-Bax reaction. A detailed kinetic 
Monte Carlo model is then used to simulate both pre- and post-mitochondrial signaling 
modules in the intrinsic apoptotic pathway. We demonstrate how a low probability of 
Bid-Bax reaction can protect normal cells from accidental activation and selectively kill 
cancer cells having overexpressed BH3 only proteins. This low probability Bid-Bax 
reaction also provides a mechanism for the non-genetic cell-to-cell stochastic variability 
in apoptotic activation. We demonstrate how increasing levels of Bcl-2 / Bax ratio can 
amplify the inherent stochastic fluctuations arising from Bid-Bax reaction and thus 
provides a mechanism for origin of cells with higher tumorigenic potential. We further 
discuss possible strategies to eliminate large cell-to-cell stochastic fluctuations in the 
intrinsic apoptotic pathway of cancer cells.  
 
Method and Results 
 
We develop and study a simplified network model of apoptotic signaling (24) that is 
triggered by the direct Bid-Bax reaction (Figure 1). In our previous computational studies 
we used Bid-tBid conversion reaction to activate the intrinsic pathway of apoptosis (8,10-
12). In this study, Bcl-2 inhibition by itself can lead to the activation of the pre-
mitochondrial signaling module through direct Bid-Bax reaction. In our model, Bcl-2 
represents all the Bcl-2 family proteins with anti-apoptotic properties. Bid is 
representative of BH3 only activators that can directly react with Bax-like multidomain 
proapoptotic molecules (captured by Bax in our model). We do not explicitly simulate 
BH3 only sensitizers (such as Bad or Bik) the effect of which can be simulated by 
varying Bcl-2 concentrations.     
 
Given the lack of knowledge of Bid-Bax reaction constants, we use our simulations to 
estimate a low probability of reaction (KA~ 2 x 105 M-1) that can activate the pathway 
when Bid and Bax are significantly over-expressed, as found in cancer cells, but would 
prevent accidental activation in normal cells. An order of magnitude variation in the 
affinity constant (KA) is possible and can still capture many of the qualitative results. 
Such low probability of reaction generates inherent stochastic fluctuations, and can cause 
large cell-to-cell variability in apoptotic activation as could be assessed by variability in 
cytochrome c release.  Anti-apoptotic action of Bcl-2 like inhibitors rely on its binding to 
Bid and Bax, and thus overexpression of Bcl-2 proteins is a mechanism of apoptotic 
resistance of cancer cells that are equipped with higher concentrations of Bid and Bax 
molecules.  Bid-Bcl-2 reaction constant is also assumed to be low (KA~ 2 x 106 M-1) in 
proportion to the low activation constant of direct Bid-Bax reaction (compared to tBid-
Bax reaction constant whose value is known to be KA~ 2 x 107 M-1). Bid-Bax-Bcl-2 
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creates a regulatory loop network in the pathway and we study the effect of variation in 
concentrations of all three molecules that constitutes the loop structure. Variations in Bcl-
2 can capture the effect of post-translational cellular variability in protein level as well as 
the action of targeted inhibitors such as BH3 mimetic agents. Cytochrome C is released 
into the cytosol in an all-or-none manner when Bax activation reaches a pre-assigned 
threshold value (25). We use a stochastic differential equation based model of the pre-
mitochondrial signaling module to elucidate the mechanisms of stochastic fluctuations 
arising from low probability Bid-Bax reactions. A detailed computational study is carried 
out using kinetic Monte Carlo (MC) simulations of pre- and post-mitochondrial signaling 
events (8). In the MC model, cytochrome c release leads to cytochorme c – apaf binding 
and the subsequent formation of multi-molecular complex apoptosome.  Low probability 
of apoptosome formation generates additional stochastic variability in apoptotic 
activation, but once formed, induces rapid activation of downstream effecter caspases -9 
and -3 (8, 26). Activation of caspase-3 is taken to be a final readout of apoptotic death 
signaling in a cell and we use Monte Carlo simulations to measure the time-course of 
caspase-3 activation at a single cell level.     
 
Signaling reactions that describe binding-unbinding between the i-th pair of molecular 
reactants (Ai + Bi  Ci) are modeled by the following set of stochastic differential 
equations   
 
W is a Weiner process (27, 28). Stochastic equations were derived from the 
corresponding master equations that describe the signaling reaction of a given type (27). 
All three molecules in the Bid-Bax-Bcl-2 regulatory loop undergo binding-unbinding 
reaction with each other that can be described by stochastic equations as shown above. In 
addition, Bax can get converted to an activated form when dissociating from the Bid-Bax 
complex. Such catalytic activation reaction is included in the model using a term similar 
to the dissociation reaction and a similar rate constant. The stochastic differential 
equation (SDE) that captures low probability Bid-Bax association was solved using a 
Poisson Runga-Kutta scheme (29). In this method, the number of times a specific 
reaction channel fires in a given time t is a Poisson random variable with mean λt and 
variance λt, where λ is the propensity function. For the Bid-Bax association reaction λ = 
kon[Bid][Bax] where [] denotes the concentration of a molecular species. All other 
reaction SDEs was solved using the standard Euler-Maruyama numerical scheme of 
solving stochastic differential equations (29, 30).  The system is partitioned into subsets 
of slow and fast reactions in a manner such that the slow Bid-Bax binding reaction is 
considered with a stepsize of τ within which all other (fast) reactions are repeatedly 
solved (29).   
 
Bax was not activated when we used regular concentrations (as found in normal cells): 
Bid = 20, Bax = 50, Bcl-2 = 45 (molecules). Molecular numbers are estimated for a 1 
µm3 volume from known molar concentrations (31) and discussed in detail in our 
previous work (8,10-12). A two-fold overexpression in Bid and Bax, however, activated 
Bax, and hence the pre-mitochondrial signaling module, in a stochastic manner. Thus, 
dAi = dBi = !dCi = !koni AiBidt ! koni AiBi dW + koffi Cidt + koffi Ci dW
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even when all the cellular parameters remain identical in a cell population, inherent 
stochastic fluctuations in the Bid-Bax reaction generates large cell-to-cell variability in 
cytochrome c release. Kinetic reaction rate constants for the low probability Bid-Bax 
reaction determine the overexpression levels in Bid (and Bax) molecules needed for 
activation as well as the extent of cell-to-cell stochastic variability in Bax activation. 
Cytochrome C release, as a result of threshold Bax activation, took longer as increasing 
number of Bcl-2 is used: 45, 450, and 675 (Bid = 200, Bax = 500, Figure 2). Cell-to-cell 
stochastic variability in cytochrome c activation, which arises due to low probability of 
Bid-Bax association reaction, also increases with increasing Bcl-2 levels and remains 
sensitive to the Bcl-2 / Bax ratio. As the Bcl-2 / Bax ratio exceeds 1 in our model, a 
significant increase in stochastic variability in cytochrome c release is resulted as can be 
seen from Figure 2. Very high Bcl-2 levels (> 5 times Bax) leads to strong inhibition of 
low probability Bid-Bax reaction and thus provides a mechanism for apoptosis resistance 
of cancer cells. The threshold Bcl-2 level (to inhibit Bax activation) can be estimated by 
considering the rate equations of Bid-Bax and Bcl-2-Bax. Assuming Bcl-2-Bax reaction 
overwhelms available Bax molecules when Bcl-2 / Bax ratio exceeds α (Bcl-2 ≥ α Bax, 
α is a constant) 
 
 
konBcl2!Bax[Bcl2][Bax] " koffBcl2!Bax[Bcl2-Bax]
# konBcl2!Bax Bcl20 ! [Bcl2-Bax]( ) Bax0 ! [Bcl2-Bax]( ) = koffBcl2!Bax[Bcl2-Bax]
# konBcl2!Bax $ Bax0( ) ! [Bcl2-Bax]( ) Bax0 ! [Bcl2-Bax]( ) = koffBcl2!Bax[Bcl2-Bax]
assume Bax0 ! [Bcl2-Bax] ! 1  (small)
konBcl2!BaxBax0 $ !1( ) " koffBcl2!Bax[Bcl2-Bax]
# konBcl2!Bax[Bcl2-Bax] $ !1( ) " koffBcl2!Bax[Bcl2-Bax]
# $ !1( ) ! koff
Bcl2!Bax
konBcl2!Bax
=
2x10!2
0.33x10!2
#$ ! 7  
 
Given the time-scale over which we solve the signaling reactions, Bcl-2 / Bax ~ 5 
completely blocked Bax activation and cytochrome c release (over a wide range of Bid 
and Bax overexpressions). Thus variation in Bcl-2 levels can be a mechanism used by 
cancer cells to create heterogeneity, such as cancer stem cells, in apoptotic resistance 
within a tumor. A ten-fold overexpression of Bid and Bax, but keeping the Bcl-2 level at 
its normal, diminished cell-to-cell stochastic variability in a significant manner. Such a 
result can be seen from comparing the deterministic and stochastic terms in the SDE for 
Bid-Bax reaction.  
 
konBid!Bax[Bid][Bax] ~ konBid!Bax[Bid][Bax]
Assuming [Bid] " [Bax] ~ x
x ~ 1 / konBid!Bax ~ 500
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Thus one could observe a stochastic to deterministic transition within the intrinsic 
pathway of cancer cells when Bcl-2 levels are low or inhibited in a significant manner. 
One can compare the Bcl-2–Bax binding / unbinding reaction terms and estimate that the 
ratio Bax / Bcl-2 ~ 6 (as done above) is sufficient to overcome the Bcl-2 inhibition of 
Bid-Bax reaction. Thus, when Bax / Bcl-2 ratio exceeds a threshold value, as well as the 
product of Bid and Bax concentrations is higher than 1/√kon for the Bid-Bax association 
reaction, one expects a stochastic to deterministic transition in the release of 
mitochondrial cytochrome c, induced by the pre-mitochondrial signaling activation. Such 
a stochastic to deterministic transition will be unique to apoptotic activation in cancer 
cells and thus it can play a crucial role in developing a successful strategy for killing 
cancer cells by targeting the intrinsic pathway. Otherwise, inherent stochastic variability 
in the activation of pre-mitochondrial signaling module is a characteristic feature of 
cancer cell death, and, partly explains the variability in apoptotic vulnerability among 
cancer cells as proposed by cancer stem cells (1, 2). Variability in the amounts of 
Bid/Bax/Bcl-2, as may exist among cancer cells of a clonal population, further modulates 
the susceptibility to apoptotic activation and its stochastic variability, and thus provides 
additional mechanism for the generation of cancer stem cells.  
 
In our kinetic Monte Carlo simulation scheme, a set of signaling molecules that belong to 
the pre- and post-mitochondrial signaling modules are initially distributed randomly and 
uniformly (8).  Signaling molecules are then randomly sampled for diffusion and reaction 
moves with predefined probability constants. Probabilistic parameters used in our 
simulations are estimated from known values of kinetic and diffusion rate constants (8, 
31). Estimation of molecular numbers (~ 0.6 x nano-molar concentration x V µm3) for the 
simulation volume has been discussed in our previous work (8,10-12). For Bid (33.3 nm), 
Bax (83.3 nm), Bcl-2 (75 nm) levels found in normal cells, a Bid-Bax association 
constant of 2 x 103 M-1 s-1  (compare the same for tBid-Bax: 2 x 105 M-1 s-1), and a 
dissociation constant same as that of tBid-Bax reaction: Koff = 0.02 s-1 (KA = 2 x 107 M-1), 
protect cells from apoptosis. A two-fold increase in Bid and Bax level still did not 
activate Bax but that would have happened with a ten-fold higher Bid-Bax association 
constant. The effect of low rate constant Bid-Bax reaction on Bax activation is stronger in 
the Monte Carlo model than in the SDE model which can be attributed to the additional 
requirement of spatial encounter of reactant molecules (by diffusive transport) in the 
Monte Carlo model. We use the value of Kon = 2 x 103 M-1 s-1 for all further simulations. 
Slight variations in the value of this association constant would not change the qualitative 
results presented here.   
 
Increasing the level of Bid and Bax by ten-fold but keeping the Bcl-2 concentration at a 
normal level led to significant Bax activation and cytochorme c release (Figure 3). Bcl-2 
over-expression has been observed in a variety of cancer cells and is a marker for poor 
prognosis (21-23). In CD34+ leukemia cells, possibly a stem cell phenotype, Bcl-2 has 
been shown to be highly over-expressed  (32,33). Keeping the concentrations of Bid and 
Bax fixed at a ten-fold overexpression, but gradually increasing the levels of Bcl-2, 
diminished Bax activation. The fraction of cells in which cytochrome c was released, at a 
given time point, also decreased with increasing concentrations of Bcl-2. Cell-to-cell 
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stochastic variability in the time-scale of cytochrome c release increased with increasing 
Bcl-2 levels (Figure 3). For very high Bcl-2 concentrations (Bcl-2 / Bax ~ 5), even when 
Bid and Bax are ten-fold overexpressed, cytochrome c release was significantly inhibited. 
Formation of post-mitochondrial apoptosomes, modeled as a multimolecular cytochrome 
c- apaf complex, led to additional cell-to-cell variability in apoptotic activation as can be 
seen in Figure 4. The percentage of apoptotic cells, as measured by full caspase-3 
activation, is shown in Figure 5 for various values of Bcl-2 inhibition and also at different 
time instants. The effect of Bcl-2 inhibition on caspase-3 activation is more pronounced 
at early times (~ 3 hours) of signaling. Increasing the overexpression level of Bid and 
Bax, but keeping the Bcl-2 / Bax ratio fixed, enhanced Bax activation. Thus in cancer 
stem cells, if high antiapoptotic Bcl-2 levels are accompanied with similar high 
expressions of Bid and Bax (keeping the Bcl-2 / Bax ratio fixed), inhibiting Bcl-2 levels 
would actually lead to more pronounced apoptotic death of cancer stem cells than that of 
regular cancer cells. Bcl-2 inhibition in the presence of high levels of Bid and Bax, as 
also found in the theoretical analysis of stochastic equations, would significantly diminish 
cell-to-cell stochastic variability in apoptotic activation of cancer cells. However, if high 
Bcl-2 expression is also accompanied with a high Bcl-2 / Bax ratio, then alternative 
strategies, such as removing the BH4 domain or opening up the BH3 domain of Bcl-2 
(34) to make it proapoptotic, would selectively kill cancer stem cells. Bid truncation to 
tBid, could be another potential option in such cases of high Bcl-2/Bax ratio. Thus two 
important cellular parameters modulate cytochrome c release and as well as cell-to-cell 
variability in apoptosis resistance: (i) over-expression level of Bax and Bid like BH3 only 
proteins, (ii) Bcl-2 / Bax ratio. Over-expression of Bax and Bid underlies the specific 
killing of cancer cells, especially when Bcl-2 inhibition can be removed.  Bcl-2 / Bax 
ratio determines the degree of apoptosis resistance and leads to heterogeneity among 
cancer cells.  
 
Discussion 
Recent experiments have conclusively shown the existence of large cell-to-cell variability 
in apoptotic activation through the intrinsic mitochondrial (type 2) pathway (11-13, 26). 
All-or-none type behavior in cytochrome c release and capase-9 /3 activation, along with 
large cell-to-cell variations in the time-scale of such activation events, characterize cell-
to-cell fluctuations in apoptotic activation. Molecular mechanism of cell-to-cell 
variability remains a fundamental question in the biology of apoptosis. Cellular 
variability in pro- and anti- apoptotic protein levels that act upstream of mitochondrial 
outer membrane permeabilization (MOMP), coupled with a rapid release of cytochrome c 
once a threshold apoptotic stress has gathered on mitochondria, can cause such cell-to-
cell variability in cytochrome c release and thus downstream activation of caspases (13). 
However, even when all the cellular parameters such as relevant protein concentrations 
remain identical in a cell population, inherent stochastic fluctuations in signaling 
reactions can cause large cell-to-cell stochastic variability (8-10). Our earlier 
computational studies indicated that inhibition of tBid-Bax reaction by large amount of 
Bcl-2 (11,12) and low probability of apoptosome formation (8, 26) are two possible 
mechanisms that can generate such inherent stochastic fluctuations in apoptotic activation 
of normal and cancer cells (35, 36). In this study, we show that the low probability Bid-
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Bax reaction is another dominant mechanism for generating inherent stochastic 
fluctuations in cell death and such a mechanism is highly relevant for cancer cells. 
 
Using a set of stochastic differential equations and kinetic Monte Carlo simulations we 
elucidated the stochastic nature of Bax activation that occurs through a low probability 
Bid-Bax reaction. We carried out apoptosis simulations for various values of Bid, Bax, 
and Bcl-2 proteins and gathered quantitative information about apoptotic activation.  
Variations in Bid and Bax levels as well as the Bcl-2 / Bax ratio modulates cell-to-cell 
variability in apoptotic activation arising from stochastic Bid-Bax reaction. 
Overexpression of Bid like (BH3 only) proteins and Bax proteins, as possibly found in 
cancer cells, reduces the apoptotic threshold for cancer cells setting them on the verge of 
apoptotic collapse, but those cells remain protected by highly overexpressed antiapoptotic 
Bcl-2 like proteins. Our results indicate how a stochastic to deterministic transition in the 
pre-mitochondrial signaling module can provide unique opportunity for cancer therapy 
that relies on the apoptotic activation of the intrinsic pathway.  
 
Stochastic activation of single cells due to low probability of Bid-Bax reaction and 
cellular variation in protein levels would both regulate apoptosis resistance in single cells. 
Such heterogeneity in apoptosis resistance can be a primary mechanism for generating 
heterogeneity in a tumor population. Thus single cancer cells will get killed in a 
stochastic manner in a xeno-transplantation assay and only a fraction of cells can survive 
the assault of activated immune cells. In a modified xeno-transplantation assay, such as in 
immunocompromised NOD / SCID IL-2rg-/- mice, less resistant cancer cells having lower 
Bcl-2 / Bax ratio would survive and produce full-blown tumors. However, only cancer 
stem cells that are highly resistant to apoptosis, at least partly due to over-expression of 
Bcl-2 like proteins (and high Bcl-2 / Bax ratio), would survive in NOD / SCID mice. 
Experimental studies that would undertake quantitative measurement of signaling 
proteins in the apoptotic pathway of cancer cells, including in cancer stem cells, will 
further strengthen the results obtained from our computational studies. Previous studies 
indicated presence of high Bcl-2 levels in cancer stem cell phenotype such as 
CD34+CD38- cells in leukemia. CD34+CD38- leukemic stem cells were found to be 
only a small fraction of cancer cells in a variety of leukemia (5-7). In contrast, in KG1a, a 
very aggressive form of acute myeloid leukemia (AML), over 90% of the cells has the 
CD34+CD38- phenotype (7). Thus one could expect a high frequency of cells having 
tumorigenic potential when single KG1a cells are transplanted into NOD / SCID mice 
and provides an opportunity to test whether any variations in tumorigenic potential would 
arise from inherent stochastic fluctuations in apoptosis resistance. In general, a 
combination of the stochastic factor and variations in cellular protein levels would 
generate significant heterogeneity within a tumor cell population and such heterogeneity 
would also heavily depend on the cell type under consideration.       
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Figures 
 
Figure 1. Schematic of a simplified network for the intrinsic (mitochondrial) pathway of 
apoptosis. Bid-Bax reaction activates the pre-mitochondrial signaling module resulting in 
release of mitochondrial cytochrome c and activation of effector caspases in the post-
mitochondrial signaling module.    
 
Figure 2. Cytochrome C release, as a result of threshold Bax activation in the SDE model, 
is plotted for single cells. The number of Bcl-2 molecules is varied in our simulations; 
Bcl-2 = 45, 450, and 675 are used (Bid = 200, Bax = 500). Rapid all-or-none type release 
of cytochrome c is approximated by a sharp spike (step function) and normalized data is 
shown. Note, the time-scale of cytochrome c release significantly changes as the Bcl-2 / 
Bax ratio exceeds one.  
 
Figure 3. Single cell activations obtained from Monte Carlo (MC) simulations of the 
intrinsic pathway of apoptosis. We show the release of cytochrome c (normalized data in 
sharp-rising approximation) for various values of Bcl-2 = 45, 450, and 900 (Bid = 200, 
Bax = 500). Data is shown up to 108 MC steps (1 MC step = 10-4 sec.).  
 
Figure 4. Time course of caspase-3 activation, as readout for downstream apoptotic 
activation, is shown for single cells.  Simulations are run for 5 x 108 MC steps (1 MC step 
= 10-4 sec.). Normalized data is shown for various values of Bcl-2 = 45, 450, and 900 
(Bid = 200, Bax = 500).  
 
Figure 5. Percentage of apoptotic cells, as measured by full caspase-3 activation, is 
shown for various values of Bcl-2 inhibition: Bcl-2 = 45, 450, 900, 1350, 1800, and 2250 
(left to right). Data is shown for three different time instants: t = 108, 2 x 108, and 5 x 108 
Monte Carlo steps. Cells used to estimate apoptotic activation include cells for which 
single cell data is shown in Figures 3 and 4. Data is not shown if there is no activation 
(for specific parameter values).  
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